Saberry (amla extract) shows superior antidiabetic and anti-dyslipidemia activities compared to Metformin
Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by hyperglycemia, caused mainly by insulin resistance or inadequate insulin production. The present study provides strong evidence that Saberry – the Amla extract by Sabinsa - at 1g and 2g/day is safe, well tolerated and showed superior antidiabetic and anti-dyslipidemia activities compared to the pharmaceutical drug, Metformin.
The efficacy of Emblica officinalis extract (EOE) containing 10% β-Glucogallin - Saberry® - was compared against Metformin in newly diagnosed subjects with diabetic dyslipidemia which is a significant factor in cardiovascular disease. Daily administration with EOE-1g, EOE-2g, or Metformin 500mg for 90 days significantly decreased fasting blood sugar and postprandial blood glucose (FBS and PPBS), hemoglobin A1c (HbA1c) and lipid levels in all three treatment groups. The FBS, PPBS and HbA1c were significantly lower in the EOE-2g group compared with Metformin and EOE-1g groups. The reductions in LDL and TC in the EOE-2g group were also significantly higher than in the EOE-1g group and were comparable to the Metformin group. No serious adverse effects were observed in any study participants. EOE-1g and 2g/day are safe and potent antidiabetic agents, with comparable efficacy to the pharmaceutical drug, Metformin. Supplementation with EOE- 2g/day even showed greater efficacy than Metformin in reducing circulating glucose levels.
Natural products such as standardized extract of E. officinalis is an attractive lead as a potential supplement for the management of T2DM with associated dyslipidemia since their low toxicity allows them to be used as long-term prophylactics
Saberry ® was specifically studied by Sabinsa. It is a light-colored powder extracted from selected fresh fruits ("gooseberries"), by a protective process and standardized for 10% β-Glucogallin. It has significant potential as a digestive aid (amla is traditionally known to support digestive functions), also known for its antioxidant spectrum and hepato-protective activity: it reduces the severity of hepatic fibrosis induced by carbon tetrachloride (CCl4 ) and thioacetamide (TAA). Improvement in liver function was observed by measuring the levels of aspartate aminotransaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and bilirubin in serum, and more recently a greater efficacy than Metformin in reducing circulating glucose levels in Type 2 diabetes mellitus (T2DM) subject.
Internal studies on β-glucogallin have shown an IC50 value of 53.7 µg / ml for the inhibition of aldose reductase (anti-diabetes).
Keywords: Diabetes, Dyslipidemia, Metformin, Emblica officinalis, β-Glucogallin, Hyperglycemia
Novel Emblica officinalis extract containing β-Glucogallin vs. Metformin: A randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia, Muhammed Majeed et al., Food & Function, 2022, DOI: 10.1039/D2FO01862D
see the study : https://pubs.rsc.org/en/content/articlelanding/2022/fo/d2fo01862d